Key Mesenchymal Precursor Cell Patents Granted In United States And China
MELBOURNE, Australia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been granted three key new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of the People's Republic of China. These patents deliver major commercial advantages and offer long term protection in these territories for the company's products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform. In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive rights through to March 2029 to compositions-of-matter covering its current products. This patent extends by more than seven years Mesoblast's exclusive commercial rights in the United States, the world's largest healthcare market, to MPC compositions-of-matter beyond those rights already conferred by USPTO patents 7,122,178 and 8,158,118 whose expiry had previously been extended to November 2021. In China, patents CN200580040212.1 and CN200580039970.1 provide Mesoblast with exclusive MPC product commercial rights and protection through to 2025. These patents provide Mesoblast with long-term composition-of-matter protection for the company's MPC products derived from an unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord, and dental pulp. These Chinese patents underpin Mesoblast's corporate strategy to target the world's largest emerging market for regenerative medicines, and to protect its manufacturing processes and know-how. Mesoblast Limited
Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for a broad range of major clinical diseases, including inflammatory and immunologic conditions, diabetes and its complications, orthopedic spine conditions, and cardiovascular disorders. www.mesoblast.com
CONTACT: Julie Meldrum
Global Head of Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
